-transparent.png){kind=logo}
Fifty-two adults treated previously with either acute leukemia (43 patients) or blastic-phase chronic myelogenous leukemia (nine patients) received 4-demethoxydaunorubicin (20 to 45 mg/sq m) i.v. over 2 to 3 days. Three of the ten patients with acute lymphocytic leukemia achieved a complete remission (CR) lasting 5 to 7 weeks. Five of the 28 patients with acute nonlymphocytic leukemia achieved a CR lasting 5 to 80 weeks. All remissions were induced with one course of treatment with a median time to CR of 28 days (range, 22 to 40 days). None of the patients with blastic chronic myelogenous leukemia or secondary leukemia achieved a CR. The drug was well tolerated; mucositis (36%), nausea and vomiting (35%), and hepatic dysfunction (26%) were the most common side effects. Pharmacokinetic observations on five patients demonstrated multiphasic clearance of 4-demethoxydaunorubicin and extensive formation and prolonged retention of 4-demethoxy-13-hydroxydaunorubicin; that metabolite accumulated in plasma on repeated daily dosing. 4-Demethoxydaunorubicin has sufficient antileukemic activity in both acute lymphocytic leukemia and acute nonlymphocytic leukemia to warrant a prospective comparison, in combination regimens, against the conventional anthracyclines, daunorubicin and/or doxorubicin.
A N Daghestani, and
Z A Arlin, and
B Leyland-Jones, and
T S Gee, and
S J Kempin, and
R Mertelsmann, and
D Budman, and
P Schulman, and
R Baratz, and
L Williams
January 1984,
Investigational new drugs,
A N Daghestani, and
Z A Arlin, and
B Leyland-Jones, and
T S Gee, and
S J Kempin, and
R Mertelsmann, and
D Budman, and
P Schulman, and
R Baratz, and
L Williams
June 1987,
Cancer research,
A N Daghestani, and
Z A Arlin, and
B Leyland-Jones, and
T S Gee, and
S J Kempin, and
R Mertelsmann, and
D Budman, and
P Schulman, and
R Baratz, and
L Williams
April 1988,
European journal of cancer & clinical oncology,
A N Daghestani, and
Z A Arlin, and
B Leyland-Jones, and
T S Gee, and
S J Kempin, and
R Mertelsmann, and
D Budman, and
P Schulman, and
R Baratz, and
L Williams
January 1987,
Haematology and blood transfusion,
A N Daghestani, and
Z A Arlin, and
B Leyland-Jones, and
T S Gee, and
S J Kempin, and
R Mertelsmann, and
D Budman, and
P Schulman, and
R Baratz, and
L Williams
January 1984,
Investigational new drugs,
A N Daghestani, and
Z A Arlin, and
B Leyland-Jones, and
T S Gee, and
S J Kempin, and
R Mertelsmann, and
D Budman, and
P Schulman, and
R Baratz, and
L Williams
October 1993,
Gan to kagaku ryoho. Cancer & chemotherapy,
A N Daghestani, and
Z A Arlin, and
B Leyland-Jones, and
T S Gee, and
S J Kempin, and
R Mertelsmann, and
D Budman, and
P Schulman, and
R Baratz, and
L Williams
July 1986,
Cancer treatment reports,
A N Daghestani, and
Z A Arlin, and
B Leyland-Jones, and
T S Gee, and
S J Kempin, and
R Mertelsmann, and
D Budman, and
P Schulman, and
R Baratz, and
L Williams
January 1988,
Cancer chemotherapy and pharmacology,
A N Daghestani, and
Z A Arlin, and
B Leyland-Jones, and
T S Gee, and
S J Kempin, and
R Mertelsmann, and
D Budman, and
P Schulman, and
R Baratz, and
L Williams
January 1990,
Cancer chemotherapy and pharmacology,
A N Daghestani, and
Z A Arlin, and
B Leyland-Jones, and
T S Gee, and
S J Kempin, and
R Mertelsmann, and
D Budman, and
P Schulman, and
R Baratz, and
L Williams
January 1986,
Investigational new drugs,
